Search

Being part of the cell and gene therapy field is an incredible privilege, according to Frank Mathias, CEO, Oxford Biomedica.

Here’s a roundup of ten of the most eye-catching deals so far in 2025.

A look at how biosimilars can increase patient access to essential medicines, as well as improve performance in healthcare systems.

Here’s why the Cell and Gene Therapy Catapult is excited about the potential of digital twin technology.

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Using AI to improve oncology care and find the right clinical trials for patients.

Doing more to ease the challenges of antibody drug conjugate manufacturing.

And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.

The Trump administration’s move to pause federal funding while projects are vetted causes concern and lawsuits

What can we expect the US life sciences sector to look like over the course of the next four years as Donald Trump takes up his presidency?